Aubagio

Ponvory Approved in EU for Active Relapsing Forms of MS

The European Commission has approved PonvoryĀ (ponesimod) to treat adults with relapsing forms of multiple sclerosis (MS) and active disease, as defined by clinical or imaging features. The approval, which follows a recommendation from the Committee for Medicinal Products for Human Use in March, covers clinically isolated…

Safety of Oral DMTs for RRMS in Real-world Use Seen to Match Trial Findings

People with relapsing-remitting multiple sclerosis (RRMS) using approved oral disease-modifyingĀ therapiesĀ generally tolerate the treatments well, with real-world adverse event profiles similar to those seen in clinical trials, an analysis of U.S. data indicates. Results also suggest high adherence to these therapies ā€” meaning patients are usually taking the therapies…

Let’s Treat Older MS Patients With More Respect

As comic Rodney Dangerfield might have said, older people with MS “just don’t get no respect.” By older, I mean those of us who are 55 and up. By respect, I mean from researchers and some neurologists. So, as I approach my 73rd birthday, I have to tip my cap…

#AANAM ā€“ Ublituximab Reduced Relapse Rate, Disability Progression in Twin Trials

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’…

#MSVirtual2020 – Ponesimod Superior to Aubagio in Delaying Disability Progression in Relapsing MS, Trial Data Show

Janssen Pharmaceuticalsā€™ investigational oral therapy ponesimod is superior to Sanofiā€™s Aubagio (teriflunomide) in delaying disability progression in adults with relapsing multiple sclerosis (MS), according to exploratory analyses of OPTIMUM clinical trial data. These and other findings from Janssenā€™s MS research program, including on the health…

FDA Approves Kesimpta, B-cell Targeting Therapy for Relapsing MS

The U.S. Food and Drug Administration (FDA) has approved Novartis‘ Kesimpta (ofatumumab) as a self-administered treatment for adults with relapsing forms of multiple sclerosis (MS), meaning those withĀ clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary progressive MS (SPMS). According to Novartis,…

Aubagio Safely Used by 5 MS Patients With Active COVID-19 Infection

Five people with multiple sclerosis (MS) who tested positive for COVID-19Ā whileĀ being treated with Aubagio (teriflunomide)Ā Ā all developed a mild infection, had good outcomes, and experienced no disease relapses, a case study reported. These findings suggest that use of Aubagio, a disease-modifying therapy that acts on the immune system,…

Ocrevus Use Still Growing in Europe But Challenges on Horizon, Spherix Reports

Prescriptions ofĀ Rocheā€™sĀ OcrevusĀ (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching aĀ disease-modifying therapy (DMT) continue to rise in Europe, according toĀ a surveyĀ conducted byĀ Spherix Global Insights. Ocrevus, an anti-CD20 monoclonal antibody administered directly into a vein,Ā was approved in the European UnionĀ to treat active forms…

Who’s Willing to Accept More DMT Risk, You or Your Neuro?

As more high-efficacy disease-modifying therapies (DMTs) are being made available, people with multiple sclerosis have to decide how much risk they’re willing to accept in exchange for the treatment’s potential benefits. It’s a tough decision not made any easier if a patient’s neurologist is unwilling to accept much risk.